A Vieillard-Baron1, V Caille, C Charron, G Belliard, P Aegerter, B Page, F Jardin. 1. Medical Intensive Care Unit, Service de Réanimation Médicale, Centre Hospitalier Universitaire Ambroise Paré, 9 Avenue Charles de Gaulle, 92104, Boulogne Cedex, France. antoine.vieillard-baron@apr.aphp.fr
Abstract
OBJECTIVE: We previously reported that early continuous veno-venous hemodiafiltration (CVVHDF) enables rapid identification of a subgroup of patients with "refractory" septic shock and a 100% risk of death. The objective of this study was to investigate whether early administration of drotrecogin alpha (activated) (DrotAA) to this selected subgroup of septic patients at extremely high risk of death would significantly improve prognosis. METHOD: Prospective observational study in a medical intensive-care unit of a University Hospital. Twenty-three patients with refractory septic shock were included. "Refractory" shock was defined as persistent circulatory failure despite adequate circulatory support, associated with persisting lactic acidosis despite early CVVHDF. Response to CVVDHF was assessed after 6 h of this continuous procedure. Patients selected by this strategy received DrotAA infusion for four days. RESULTS: The 28-day mortality rate of the 23 patients was 39%. No difference was observed at inclusion between survivors and nonsurvivors. In patients who finally survived, 12 h of DrotAA infusion was associated with a significant decrease in lactic acidosis and in norepinephrine dose. CONCLUSION: DrotAA therapy was associated with unexpectedly high 28-day survival in patients with "refractory" septic shock.
OBJECTIVE: We previously reported that early continuous veno-venous hemodiafiltration (CVVHDF) enables rapid identification of a subgroup of patients with "refractory" septic shock and a 100% risk of death. The objective of this study was to investigate whether early administration of drotrecogin alpha (activated) (DrotAA) to this selected subgroup of septic patients at extremely high risk of death would significantly improve prognosis. METHOD: Prospective observational study in a medical intensive-care unit of a University Hospital. Twenty-three patients with refractory septic shock were included. "Refractory" shock was defined as persistent circulatory failure despite adequate circulatory support, associated with persisting lactic acidosis despite early CVVHDF. Response to CVVDHF was assessed after 6 h of this continuous procedure. Patients selected by this strategy received DrotAA infusion for four days. RESULTS: The 28-day mortality rate of the 23 patients was 39%. No difference was observed at inclusion between survivors and nonsurvivors. In patients who finally survived, 12 h of DrotAA infusion was associated with a significant decrease in lactic acidosis and in norepinephrine dose. CONCLUSION:DrotAA therapy was associated with unexpectedly high 28-day survival in patients with "refractory" septic shock.
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: E Wesley Ely; Pierre-François Laterre; Derek C Angus; Jeffrey D Helterbrand; Howard Levy; Jean-François Dhainaut; Jean-Louis Vincent; William L Macias; Gordon R Bernard Journal: Crit Care Med Date: 2003-01 Impact factor: 7.598
Authors: Bernard Page; Antoine Vieillard-Baron; Karim Chergui; Olivier Peyrouset; Anne Rabiller; Alain Beauchet; Philippe Aegerter; François Jardin Journal: Crit Care Date: 2005-11-09 Impact factor: 9.097
Authors: Jean-Louis Vincent; James O'Brien; Arthur Wheeler; Xavier Wittebole; Rekha Garg; Benjamin L Trzaskoma; David P Sundin Journal: Crit Care Date: 2006-05-09 Impact factor: 9.097
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-08 Impact factor: 17.440
Authors: Dominika Lukovic; Noemi Nyolczas; Rayyan Hemetsberger; Imre J Pavo; Aniko Pósa; Boris Behnisch; Gerhard Horak; Katrin Zlabinger; Mariann Gyöngyösi Journal: J Mater Sci Mater Med Date: 2015-09-28 Impact factor: 3.896